Cargando…

Leptin, Both Bad and Good Actor in Cancer

Leptin is an important regulator of basal metabolism and food intake, with a pivotal role in obesity. Leptin exerts many different actions on various tissues and systems, including cancer, and is considered as a linkage between metabolism and the immune system. During the last decades, obesity and l...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiménez-Cortegana, Carlos, López-Saavedra, Ana, Sánchez-Jiménez, Flora, Pérez-Pérez, Antonio, Castiñeiras, Jesús, Virizuela-Echaburu, Juan A., de la Cruz-Merino, Luis, Sánchez-Margalet, Víctor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235379/
https://www.ncbi.nlm.nih.gov/pubmed/34202969
http://dx.doi.org/10.3390/biom11060913
_version_ 1783714303710330880
author Jiménez-Cortegana, Carlos
López-Saavedra, Ana
Sánchez-Jiménez, Flora
Pérez-Pérez, Antonio
Castiñeiras, Jesús
Virizuela-Echaburu, Juan A.
de la Cruz-Merino, Luis
Sánchez-Margalet, Víctor
author_facet Jiménez-Cortegana, Carlos
López-Saavedra, Ana
Sánchez-Jiménez, Flora
Pérez-Pérez, Antonio
Castiñeiras, Jesús
Virizuela-Echaburu, Juan A.
de la Cruz-Merino, Luis
Sánchez-Margalet, Víctor
author_sort Jiménez-Cortegana, Carlos
collection PubMed
description Leptin is an important regulator of basal metabolism and food intake, with a pivotal role in obesity. Leptin exerts many different actions on various tissues and systems, including cancer, and is considered as a linkage between metabolism and the immune system. During the last decades, obesity and leptin have been associated with the initiation, proliferation and progression of many types of cancer. Obesity is also linked with complications and mortality, irrespective of the therapy used, affecting clinical outcomes. However, some evidence has suggested its beneficial role, called the “obesity paradox”, and the possible antitumoral role of leptin. Recent data regarding the immunotherapy of cancer have revealed that overweight leads to a more effective response and leptin may probably be involved in this beneficial process. Since leptin is a positive modulator of both the innate and the adaptive immune system, it may contribute to the increased immune response stimulated by immunotherapy in cancer patients and may be proposed as a good actor in cancer. Our purpose is to review this dual role of leptin in cancer, as well as trying to clarify the future perspectives of this adipokine, which further highlights its importance as a cornerstone of the immunometabolism in oncology.
format Online
Article
Text
id pubmed-8235379
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82353792021-06-27 Leptin, Both Bad and Good Actor in Cancer Jiménez-Cortegana, Carlos López-Saavedra, Ana Sánchez-Jiménez, Flora Pérez-Pérez, Antonio Castiñeiras, Jesús Virizuela-Echaburu, Juan A. de la Cruz-Merino, Luis Sánchez-Margalet, Víctor Biomolecules Review Leptin is an important regulator of basal metabolism and food intake, with a pivotal role in obesity. Leptin exerts many different actions on various tissues and systems, including cancer, and is considered as a linkage between metabolism and the immune system. During the last decades, obesity and leptin have been associated with the initiation, proliferation and progression of many types of cancer. Obesity is also linked with complications and mortality, irrespective of the therapy used, affecting clinical outcomes. However, some evidence has suggested its beneficial role, called the “obesity paradox”, and the possible antitumoral role of leptin. Recent data regarding the immunotherapy of cancer have revealed that overweight leads to a more effective response and leptin may probably be involved in this beneficial process. Since leptin is a positive modulator of both the innate and the adaptive immune system, it may contribute to the increased immune response stimulated by immunotherapy in cancer patients and may be proposed as a good actor in cancer. Our purpose is to review this dual role of leptin in cancer, as well as trying to clarify the future perspectives of this adipokine, which further highlights its importance as a cornerstone of the immunometabolism in oncology. MDPI 2021-06-20 /pmc/articles/PMC8235379/ /pubmed/34202969 http://dx.doi.org/10.3390/biom11060913 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Jiménez-Cortegana, Carlos
López-Saavedra, Ana
Sánchez-Jiménez, Flora
Pérez-Pérez, Antonio
Castiñeiras, Jesús
Virizuela-Echaburu, Juan A.
de la Cruz-Merino, Luis
Sánchez-Margalet, Víctor
Leptin, Both Bad and Good Actor in Cancer
title Leptin, Both Bad and Good Actor in Cancer
title_full Leptin, Both Bad and Good Actor in Cancer
title_fullStr Leptin, Both Bad and Good Actor in Cancer
title_full_unstemmed Leptin, Both Bad and Good Actor in Cancer
title_short Leptin, Both Bad and Good Actor in Cancer
title_sort leptin, both bad and good actor in cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235379/
https://www.ncbi.nlm.nih.gov/pubmed/34202969
http://dx.doi.org/10.3390/biom11060913
work_keys_str_mv AT jimenezcorteganacarlos leptinbothbadandgoodactorincancer
AT lopezsaavedraana leptinbothbadandgoodactorincancer
AT sanchezjimenezflora leptinbothbadandgoodactorincancer
AT perezperezantonio leptinbothbadandgoodactorincancer
AT castineirasjesus leptinbothbadandgoodactorincancer
AT virizuelaechaburujuana leptinbothbadandgoodactorincancer
AT delacruzmerinoluis leptinbothbadandgoodactorincancer
AT sanchezmargaletvictor leptinbothbadandgoodactorincancer